Navigation Links
Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range

BEIJING, Jan. 6, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today its preliminary unaudited sales range for the fourth quarter and full year ended December 31, 2010. A conference call to discuss these preliminary sales will be held on January 6, 2011 at 8:00 a.m. Eastern Standard Time (January 6, 2011 at 9:00 pm China Standard Time). The Company will issue its final unaudited fourth quarter and full year 2010 financial results on or about March 31, 2011.

Sinovac expects its fourth quarter 2010 preliminary unaudited sales to be in the range of approximately $7.8 million to $10.8 million and its full year 2010 preliminary unaudited sales to be in the range of $32 million to $35 million.  The shortfall in sales as compared to the revised total 2010 sales expectations issued in October 2010 was attributable to the weaker than expected sales of Anflu and Healive in the private market.

Dr. Weidong Yin, Chairman & CEO, commented, "We faced a challenging external market environment in 2010, which negatively impacted vaccine demand in the private market. As the company grows, we cannot avoid market-related volatility. We believe it is a great experience for Sinovac's fast-growing management team to learn and grow. Recognizing the importance of addressing this market situation, we are undertaking initiatives to adjust our sales strategy. Concurrently, we are continuing to advance our R&D projects with the aim of completing development and launching our new products. Currently, we have sufficient cash on hand to support Company's R&D activities, capacity expansion, potential M&A and international collaborations, which are the company's driving forces for future growth."

The preliminary sales ranges are preliminary unaudited estimates for the fourth quarter and full year ended December 31, 2010

ConferenceCallDetailsThe Company will host a conference call on Thursday, January 6, 2010 at 8:00 a.m. EST (January 6, 2011 at 9:00 pm China Standard Time) to review the Company's selected preliminary unaudited sales range for the fourth quarter and full year ended December 31, 2010. To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 11:00 a.m. EST on January 6, 2011 to January 20, 2011 at midnight. To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (international) and the replay pin number 364713.

A live audio webcast of the call will also be available from the Investors section on the corporate web site at A webcast replay can be accessed on the corporate website beginning January 6, 2011 and the replay will remain available for 30 days.

AboutSinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received the orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), Japanese Encephalitis, animal and human rabies, HIB and epidemic meningitis, chickenpox, mumps and rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines and has completed the field trials for an independently developed inactivated animal rabies vaccine, which is anticipated to be launched into market in 2011.

SafeHarborStatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.Helen Yang/Chris Lee
Sinovac Biotech Ltd.
Tel:  +86-10-8279-9871/9659
Fax:  +86-10-6296-6910
Email: ir@sinovac.comInvestors:
Stephanie Carrington/Amy Glynn
The Ruth Group
Tel:  +1-646-536-7017/7023
Jason Rando
The Ruth Group
Tel:  +1-646-536-7025

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovacs Stock Exchange Listing Moves to NASDAQ Global Select Market
2. Sinovac Receives SFDA Approval to Commence Clinical Trials for Inactivated Enterovirus Type 71 Vaccine
3. Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations
4. Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
5. Sinovac Receives Drug Registration Certificate from Hong Kong Department of Health for Seasonal Flu Vaccine Anflu(R)
6. Sinovac to Host Conference Call to Report Second Quarter 2010 Financial Results
7. Sinovac Holds 2010 Annual Meeting of Shareholders
8. Sinovac Schedules 2010 Annual Meeting of Shareholders
9. Sinovac Selected by Beijing CDC to Supply Hepatitis A Vaccine Healive(R)
10. Sinovac Announces Plan to Launch Offering of Common Shares
11. Sinovac Announces Recent Developments
Post Your Comments:
(Date:10/9/2015)... DIEGO , Oct. 9, 2015 Ansun ... (Infectious Disease Society of America ) regarding the compassionate ... transplant patient on a respirator who was co-infected with ... a five-day course of therapy, O 2 requirement ... the patient was able to go off the respirator ...
(Date:10/8/2015)... October 9, 2015 ® ... diagnostic colonoscopy. The NOCT study also assessed the ... --> ® ) in adult patients ... study also assessed the compliance, safety, patient acceptability ... today announced positive top line results for its ...
(Date:10/8/2015)... PITTSBURGH , Oct. 8, 2015 /PRNewswire/ ... pharmaceutical company, will host a conference call and webcast ... ET to review the value to be created for ... TASE) through Mylan,s offer to acquire the company. During ... outlines the compelling proposition for Perrigo shareholders. Mylan,s offer ...
Breaking Medicine Technology:
... IDEV Technologies, Inc. (IDEV) today announced the firm ... Australia,s regulatory agency for medical drugs and devices, for ... and peripheral procedures. "We are pleased to ... SUPERA VERITAS in the Australian market later this year," ...
... 28, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the ... Paris, France. "The data we are ... an important new treatment option for patients with multiple ...
Cached Medicine Technology:
(Date:10/10/2015)... ... October 10, 2015 , ... Story Chaser is a ... by reading various classics and inspiring stories and as words drop down and users ... animations are extremely aesthetic and can be interacted with, making it a more engaging ...
(Date:10/9/2015)... ... 2015 , ... Doctors on Liens has teamed up with a ... needed medical care to personal injury victims. When personal injury victims suffer major, ... treat the variety of conditions ailing them. With the addition of this new ...
(Date:10/9/2015)... WASHINGTON, NH (PRWEB) , ... October 09, 2015 , ... ... Sore Throat Home Exam Aid, is now available online ( ) – just ... and Prevention (CDC) says officially begins in October. However, for many in the U.S., ...
(Date:10/9/2015)... ... October 09, 2015 , ... Head Over Heels Athletic Arts ... developmental camp at the Karolyi Ranch in Huntsville, Texas on October 17-21. , ... Heels girls team head coach and executive director, said. “It's a stepping stone into ...
(Date:10/9/2015)... ... October 09, 2015 , ... Cambias ... the surrounding communities, is initiating a combined charity effort with Animal Rescue New ... in southern Louisiana. , Animal Rescue New Orleans is a non-profit organization ...
Breaking Medicine News(10 mins):
... Eye Research Institute (SERI) found that increasing the contrast ... enjoyable to the visually impaired. // ,The U.S. ... device to help millions suffering eye diseases. People who ... from macular degeneration, diabetic retinopathy and other causes of ...
... family and community medicine and colleagues developed the latest tool ... developed a tool which is called the Newest vital sign. ... based on an ice cream nutrition label. Based on the ... literacy can be calculated. , Then it is ...
... has been legalized in Canada the sex workers feel that the ... public for negotiating with their customers in public and does not ... rented flat.// The sex workers organization feels that the law will ... to brutality and killing, as they are not sure about the ...
... undergo a liver transplant at the St James's University Hospital in ... to take as long as 10 hours, in which half the ... ,Lennox developed chronic liver problems and jaundice within weeks after his ... a transplant appeared to be the only way of saving his ...
... San Diego have designed mice containing fully functional human nerve ... neurodegenerative diseases such as Parkinson's and Alzheimer's. // ... the neurons were formed in the brains of mice that ... embryos. ,Studies showed that the human stem ...
... The human brain can be manipulated to get relief from ... University in California. ,As many as eight patients were ... brains while performing // mental exercises. Standard therapy has ... possibilities can be opened through the results of the research. ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: